The immune response to normal joint proteins probably plays a critical role in the joint destruction of rheumatoid arthritis (for review, see references 1 and 2). Many patients have detectable immunity to various connective tissue components (3-5), and arthritis can be induced in rodents by immunizing them either with collagen or proteoglycans isolated from cartilage (6, 7). Localizing determinants ofconnective tissue with the capacity to generate immunogenic responses may give us a better understanding of the way in which arthritis is initiated and regulated.
where (18) . There were two separate examiners, one of whom was unaware of the identity of the treatment groups. Each mouse was scored three times a week by visual examination beginning 3 wk post-immunization and continuing through 8 wk post-immunization . In some experiments, the data were expressed as the percentage ofarthritic limbs per group ofmice, plotted either at various time points or at 6 wk post-immunization . Analyzing the number oflimbs involved rather than the number of mice permitted use ofsmaller groups. It assumed that the occurrence ofarthritis in a limb was random and not related to whether other limbs in the same mouse were involved. To confirm the validity of this assumption, the incidence of arthritis (number of animals with one or more arthritic limbs) was also analyzed at one time point, usually 6 wk post-immunization .
Measurement of Serum Antibody Titers. Mice were bled at 4 and 8 wk after immunization to test for antibodies reactive with native CII or CB peptides ofcollagen using a modification of an ELISA, previously described (19) . Briefly, native CII or the antigen to be tested was dissolved in 0.01 M acetic acid at 4 mg/ml and diluted to a final concentration of 5 Rg/ml in 0.1 M NaHC03 immediately before use. Microtiter plates (Nunc, Roskilde, Denmark) were coated by adding 100-pl aliquots of each collagen preparation to the wells, incubating overnight at VC, and washing the plates to remove unbound collagen. Sera for analysis were serially diluted with 0.15 M NaCl, 0.05 M Tris-HCI, pH 7.4, containing 0.0570 Tween 20 , and added to the collagen-coated microtiter plates in 100-ill aliquots. After incubation overnight, the wells were washed and 100 Al ofperoxidase-conjugated goat anti-mouse IgG (Cappel Laboratories, Cochranville, PA) was added. Plates were incubated for 4 h, washed, and developed using 40 mg oforthophenylenediamine dissolved in 100 ml of citrate phosphate buffer, pH 5.5, to which 40 Fd of 30% H202 was added immediately before use . After 15 min, the absorbance at 490 nm was measured using an automated reader (Vmax ; Molecular Devices, Menlo Park, CA) . A standard serum was added to each plate in serial dilutions. From these values, a standard curve was derived by computer analysis using a four-parameter logistic curve. Results are reported as units of activity, derived by comparison of test sera with the standard serum, which was arbitrarily defined as having 50 U of activity.
Statistical Analysis . The incidences of arthritis in various groups of mice were compared using either the Kruskal Wallis analysis of variance or X2 analysis with Yates' correction . Antibody levels were compared using the student's t test.
Results
Suppression ofArthritis with Intact CII. Mice injected intravenously with native or denatured CH before immunization were resistant to arthritis . By 6 wk postimmunization, the control groups, given OVA or type I collagen, had an arthritis incidence of 17/18 (94%) or 5/5 (100%), respectively ; animals given denatured CII had an incidence of 1/18 (6%); and animals given native CII had no arthritis (Table  I) . The incidence ofarthritis in groups receiving either native or denatured CII were both significantly different from OVA controls, with p <0.004 by Kruskal Wallis analysis of variance. Mice were also evaluated according to the mean percentage of arthritic limbs per group ofsix mice (Table I) . By 6 wk post-immunization, the control group injected with OVA had 56% arthritic limbs and the group given type I collagen had 46% arthritic limbs. Animals injected with denatured CII had 3% arthritic limbs and animals injected with CH had no arthritis . Both groups administered CH were significantly different from OVA controls using X2 with Yates' analysis (p <0.0001) .
All of the animals were bled at 4 and 8 wk post-immunization and tested for antibody response to native CII by ELISA . Animals given a tolerizing injection ofeither native or denatured CII before immunization had significantly lower antibody levels to CII at both 4 and 8 wk post-immunization, in comparison with control mice in- jected with OVA (Table I) . Animals given denatured CII had antibody levels intermediate to those given native CII and controls that correlated well with the incidence of disease .
The onset of arthritis was also delayed in animals given denatured CII (Fig. 1 ). Control animals given OVA had the onset of arthritis beginning day 21, followed by a rapid increase in the number of arthritic limbs. A plateau occurred N6 wk after immunization, but the animals continued to develop newly affected limbs until the termination of the study at 8 wk post-immunization . Animals given native CII before immunization had no arthritis develop throughout this study, but animals given denatured CII had the onset ofdisease beginning around day 35 post-immunization .
The suppressive effect began to fade by 8 wk after immunization, as evidenced by an increasing frequency of arthritis and by smaller differences in antibody levels .
Days Post-Immunization Suppression ofArthritis with Fragments of CII. To localize regions of the molecule responsible for inducing tolerance, CII was cleaved by treatment with CB, and the resulting peptides were individually isolated. CB peptides 11, 10, and 8 were selected for further experimentation because they comprise 75% of the entire molecule and because our earlier work (8) showed that sera from arthritic animals immunized with CII contain antibodies that recognize these peptides selectively. We injected mice with the peptides 11, 10, or 8 intravenously and challenged them 3 d later by immunization with intact CII. By 6 wk post-immunization, 92% of the animals given OVA, 69% of the animals given CB10, and 83% of the mice given CB8 were arthritic (Table II) . In contrast, only 25% of the mice given CB11 were arthritic (p <0.002). Both native CII and CB11 effectively suppressed the overall antibody responses to intact CII and to each of the CB peptides tested, while neither CB8 nor CB10 did so (Table III) .
Suppression of Arthritis in Adult Mice with a Synthetic Peptide Representing Sequences of Chick a1(II)CB11 . To further localize the most important determinant of suppression, five synthetic peptides, each 21-26 amino acids in length, were generated. These peptides corresponded to sequences of CB11 selected by comparison of CII to type I collagen and identifying areas with the greatest differences. CII and type I collagen are 70% homologous within the CB11 region, excluding glycine at every third residue. The greatest differences are confined to two areas, the first 126-140 amino acids from the NH2 terminal, and the second 240-257 from the amino terminal of al(II)CB11 . (20) . Of the five peptides tested, only CB11 122-147 had suppressive activity (Table IV) . Mice receiving CB11 122-147 had an incidence of 9/18 (50%) arthritis and 16/72 (22%) arthritic limbs, when compared with animals given OVA, which had 17/18 (94%) arthritic mice and 39/72 (54%) arthritic limbs (p = 0.05 and p = 0.01, respectively). A larger dose (5 mg/mouse) of CBll 122-147 was even more suppressive, giving 2/6 (33%) arthritic mice and 4/24 (17%) arthritic limbs, TABLE 11 Suppression of Arthritis with Collagen Fragments Female DBA/1 mice, 8 wk of age, were randomly allocated into groups of from 6 to 16 mice, and each group was injected intravenously with 250,ug of OVA, CII, CB8, CB10, or CBI 1 daily for 3 d . 3 d after the last injection, they were immunized with 100 t+g of CII . Data are expressed as the number of arthritic mice and the number of arthritic limbs per group at 6 wk post-immunization . The number of arthritic animals given CB11 and CII was significantly different from controls given OVA . " p < 0 .002 using Kruskal Wallis analysis of variance . Suppression ofArthritis by Neonatal Injection ofa Synthetic Peptide of CII . Because neonatal tolerance may be due to a different mechanism than adult tolerance, we determined which epitopes of CH were important in suppressing arthritis when the antigens were given neonatally. Using a protocol for inducing neonatal tolerance described in Materials and Methods, CB11 and three of its synthetic peptides were injected (Table V) . The structure ofthe synthetic peptide CB11 122-147 is shown in Fig. 2 .
Discussion
In this study, we have identified an epitope of CII that is of critical importance for regulation of arthritis. It has long been felt that autoimmunity to CII plays a major role in the pathogenesis ofcollagen-induced arthritis and rheumatoid arthritis as well (1-7). Therefore, identification of critical determinants of CII that trigger immune responses can lead to better understanding of the mechanisms behind their immunopathogenicity.
Our laboratory has previously shown (8) that the CB11 contained critical determinants for induction ofdisease in mice . In addition, other investigators have shown that intravenous administration of soluble CII (10), collagen-coupled spleen cells (9) , and partially purified collagenous peptides (11) are capable ofsuppressing collageninduced arthritis in rats. Yet localization of critical determinants for the suppressive phenomenon remained to be determined . We have confirmed that resistance to collagen-induced arthritis could also be induced in DBA/1 mice by intravenous injection of CII. This resistance was associated with tolerance to the immunizing antigen as measured by decreased antibody levels . Furthermore, although tolerance FIGURE 2 . Structure of a syn-137 thetic peptide that confers pro-I tection against arthritis . The induced by native collagen was profound, the phenomenon was not dependent upon native antigen. Both denatured collagen and peptide fragments derived by CB digestion were effective, although slightly less potent. The finding that denatured collagen fragments were effective is similar to that of Englert et al. (11), who found that partially purified CB peptides enriched for CB10-induced resistance in rats. However, in the DBA/1 mouse, the most potent and consistently suppressive fragment was CB11. CB10 showed a trend toward suppressing arthritis but this was not significant with the number of mice tested. It is possible that inclusion of additional animals might have identified another, perhaps less potent, tolerogenic site on CB10. It may also be that species differences exist in the recognition of tolerogenic peptides. Ofparticular importance, however, was the finding that a 26-amino acid synthetic peptide correlating with CB11 122-147 was capable ofsuppressing arthritis, whether given to adult animals or neonates. Additionally, because an overlapping peptide CB11 116-137 did not suppress arthritis, the critical determinant resides within the region CB11 137-147, an 11-amino acid stretch.
Distinct immunosuppressive epitopes have been demonstrated with several noncollagenous protein antigens. Hen egg-white lysozyme (21, 22) , insulin (23), a galactosidase (24) , and BSA (25) have all been shown to have nonoverlapping immunogenic and suppressive epitopes on the same molecule. Studies done in experimental allergic encephalomyelitis, an animal model for an autoimmune demyelinating disease, have revealed that the same epitope on myelin basic protein carries the ability to either suppress or cause disease (26) , and an additional inhibitory determinant could be found, distant from the encephalitogenic site (27) . In addition, a synthetic peptide composed of the NH2-terminal nine amino acids of myelin basic protein, when given neonatally, rendered mice resistant to subsequent disease induced by immunization with the same peptide, although such treatment did not make them resistant to disease induced by immunization with the whole rat myelin basic protein (28) . The superiority of a particular peptide over others of similar size in initiating immune responses is not completely understood. Recent studies of Grey, Gefter, and Unanue, and their coworkers (29) (30) (31) , have suggested that the immunodominant peptide may bind with greater affinity to the MHC antigen on the APC than do other peptides that have no effect on the immune response . Alternately, investigators have proposed that certain protein determinants trigger a greater diversity of T cells to respond with a wider range of fine specificities than other determinants can induce (32) . These two hypothetical mechanisms may both be playing a role in the case of the immune response to collagen .
In addition, mechanisms have been proposed to explain the phenomenon that intravenous injection of a protein can lead to profound suppression of the subsequent immune response to that antigen . Suppression may be the property of a particular cell, or an intrinsic property of the immune system, or carried out by known components that become suppressive only under particular circumstances (33) . Possibly, prior exposure to exogenous peptide causes inactivation or deletion of certain T cell clones, as has been proposed in neonatal tolerance to cytochrome and lysozyme peptides (28, 34) . The induction of T cells capable of suppressing Th cells, either by secretion of lymphokines or via cytotoxicity, has also been proposed (33) .
In addition, the display ofantigen on inappropriate APC may result in the inactivation, rather than the activation, ofspecific T cells (35) . The suppression ofcollageninduced arthritis with intravenous injection of CII has been reported to be antigen specific and transferrable with cells to naive animals (36) (37) (38) . Recent studies showed abrogation ofsuppression of CIA by cyclophosphamide treatment (39) and suppression of CIA by a T cell hybridoma (40) . This suggested that T cells mediated the suppression of CIA. We have found that CD4+ cells play a role in the suppressive phenomenon induced by intravenous injection of CII (41), but a role for each of the other mechanisms that have been proposed cannot be ruled out.
We have successfully suppressed arthritis by peptide-induced tolerization . Further studies are currently underway to determine which amino acids ofCBll 122-147 are pivotal for its immunological activities in the DBA/l mouse. A better definition of determinants critical for regulation of arthritis may lead to improved therapies exploiting the observation that tolerance to certain immunogenic epitopes of autoimmune proteins can result in a downregulation of the immune response and ultimately of the autoimmune disease.
Summary
We have previously reported that collagen-induced arthritis can be suppressed by intravenous injection of native type II (CII) but not type I collagen . We have now identified denatured fragments ofCII capable ofsuppressing collagen-induced arthritis and inducing tolerance. Purified CII was cleaved with cyanogen bromide (CB), and the major resulting peptides were isolated. Female DBA/1 mice were administered OVA, native CII, or one ofthe CB peptides, intravenously, before immunization with native CII. 6 wk after immunization, mice tolerized with CII or CBll had a markedly lower incidence of arthritis compared with controls . There was a correlation between the overall antibody response and the incidence of arthritis. In addition, animals tolerized with either CII or CB11 had a decreased antibody response not only to CII, but also to each of the other CB peptides tested . To identify the epitope involved in suppression of arthritis, five synthetic peptides, 21-26 amino acids in length, corresponding to selected regions of CB11, were generated. Each ofthe peptides was injected intravenously into mice before immunization . Only one ofthese, CB11 122-147, was capable ofsuppressing arthritis. In addition, mice given the synthetic peptide CB11 122-147 neonatally were suppressed for arthritis and antibody responsiveness when immunized with CII at 8 wk of age. Thus, we have identified CB11 122-147 as an epitope of CII important in induction of tolerance and suppression ofdisease. Further experiments narrowing down the pivotal amino acids for the immunogenicity ofthis epitope and the role this epitope plays in induction and regulation of disease will enhance our understanding of how the immune response to collagen affects autoimmune arthritis.
